Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

Published:2021-09-01 Issue:9 Volume:7 Page:1368
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Gettinger Scott N.¹,Redman Mary W.²³,Bazhenova Lyudmila⁴,Hirsch Fred R.⁵,Mack Philip C.⁶,Schwartz Lawrence H.⁷,Bradley Jeffrey D.⁸,Stinchcombe Thomas E.⁹,Leighl Natasha B.¹⁰,Ramalingam Suresh S.¹¹,Tavernier Susan S.¹²,Yu Hui⁵,Unger Joseph M.²³,Minichiello Katherine²³,Highleyman Louise²,Papadimitrakopoulou Vassiliki A.¹³,Kelly Karen⁶,Gandara David R.⁶,Herbst Roy S.¹

Affiliation:

1. Yale Cancer Center, New Haven, Connecticut

2. SWOG Statistical Center, Seattle, Washington

3. Fred Hutchinson Cancer Research Center, Seattle, Washington

4. University of California San Diego Moores Cancer Center, La Jolla

5. Mount Sinai Health System, New York, New York

6. University of California Davis Comprehensive Cancer Center, Sacramento

7. Columbia University Medical College, New York, New York

8. Washington University School of Medicine, St Louis, Missouri

9. Duke University School of Medicine, Durham, North Carolina

10. Princess Margaret Hospital, Toronto, Ontario, Canada

11. Department of Hematology and Oncology, Emory University, Atlanta, Georgia

12. Idaho State University School of Nursing, Pocatello

13. The University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2781889/jamaoncology_gettinger_2021_oi_210035_1631288540.96119.pdf

Reference29 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.;Borghaei;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.;Brahmer;N Engl J Med,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.;Herbst;Lancet,2016

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.;Rittmeyer;Lancet,2017

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.;Reck;N Engl J Med,2016

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer;Frontiers in Pharmacology;2024-02-05

2. Tumor-derived KLK8 predicts inferior survival and promotes an immune-suppressive tumor microenvironment in lung squamous cell carcinoma;BMC Pulmonary Medicine;2024-01-25

3. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis;Frontiers in Immunology;2024-01-22

4. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

5. RACGAP1 promotes the progression and poor prognosis of lung adenocarcinoma through its effects on the cell cycle and tumor stemness;BMC Cancer;2024-01-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3